CPSC Exempts Powder Form of 2 Drugs from Child-Resistant Packaging
The Consumer Product Safety Commission has issued a final rule, effective July 22, 2011, which amends its child-resistant packaging requirements to exempt powder formulations of two oral prescription drugs, colesevelam hydrochloride (currently marketed as Welchol®) and sevelamer carbonate (currently marketed…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
as Renvela®), which are indicated to reduce elevated LDL cholesterol levels and improve glycemic control in adults with type 2 diabetes mellitus, and for the control of elevated serum phosphorus in chronic kidney disease patients on dialysis, respectively. The rule exempts these prescription drug products on the basis that child-resistant packaging is not needed to protect young children from serious injury or illness.